预约演示

更新于：2025-05-07

Thyroiditis, Chronic

慢性甲状腺炎

更新于：2025-05-07

基本信息

别名

Chronic Thyroiditis、Chronic thyroiditis、Chronic thyroiditis (disorder)

+ [12]

简介

an inflammation of the thyroid gland that frequently results in hypothyroidism (lowered thyroid function)

关联

项与慢性甲状腺炎相关的药物

Liothyronine Sodium

碘塞罗宁钠

靶点

THR

作用机制

THR激动剂

在研机构

King Pharmaceuticals Research & Development LLC [+1]

原研机构

Pfizer Inc.

在研适应症

甲状腺肿 [+8]

非在研适应症

新型冠状病毒感染 [+1]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1956-05-08

项与慢性甲状腺炎相关的临床试验

NCT06954220

/ RecruitingN/A

Baduanjin Exercises on Shoulder Dysfunction Post Thyroidectomy

This study will be carried out at the outpatient clinic of the faculty of physical therapy, Cairo university, El Galaa general hosbital after referral from endocrine surgeon. Participants will perform these exercises in a room supervisor physiotherapist.
All participants will sign a written consent form after receiving full information about the purpose of the study, procedure, possible benefits, privacy, and use of data.

开始日期2025-04-25

申办/合作机构

Mti Medical

NCT06077084

/ CompletedN/AIIT

High Versus Moderate Intensity Neck Strengthening Treatment for Improving Disability, Neck Muscle Morphometry and Composition in Non-Specific Chronic High Versus Moderate Intensity Neck Strengthening Treatment for Improving Disability, Neck Muscle Morphometry and Composition in Non-Specific Chronic Neck Pain

This study aims to investigate the effects of exercise interventions on neck muscle morphometry and composition in individuals with chronic non specific neck pain. The participants will be randomly assigned to either a moderate intensity or a high intensity neck strengthening program. The primary outcomes include neck disability. Secondary outcomes include changes in muscle volume and fat infiltration in the neck muscles measured using MRI, pain intensity, anxiety, and depression. The results of this study will contribute the future rehabilitation strategies.

开始日期2021-02-01

申办/合作机构

Universite de la Reunion

[+1]

100 项与慢性甲状腺炎相关的临床结果

登录后查看更多信息

100 项与慢性甲状腺炎相关的转化医学

登录后查看更多信息

0 项与慢性甲状腺炎相关的专利（医药）

登录后查看更多信息

939

项与慢性甲状腺炎相关的文献（医药）

2025-04-01·Current Pharmaceutical Biotechnology

Role of Medicinal Plants in the Management of Multiple Sclerosis

Article

作者: Roy, Amit ; Verma, Rajan ; Gupta, Aaryan ; Roy, Arpita ; Raja, Vaseem ; Sharma, Kuldeep

There is a rapid spread of Multiple Sclerosis disorder across the globe, around 2.8 million cases of Multiple Sclerosis in the world. Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by demyelination, neuroinflammation, and a wide spectrum of clinical manifestations. Many drugs have been tested on MS patients but there is no effective treatment for MS till now. So to inhibit the symptoms caused by MS we performed a study in which we identified various naturally occurring materials with neuroprotective effects on the body that can treat Multiple Sclerosis. The therapeutic strategies portion of the paper reviews the array of disease-modifying therapies currently available for MS management. This paper evaluated their mechanisms of action, efficacy, and safety profiles. It also addressed emerging treatment paradigms by using different naturally occurring materials, including personalized medicine approaches and novel therapies in development. This paper provides a comprehensive overview of the current state of knowledge regarding MS, focusing on its pathogenesis, diagnostic approaches, and therapeutic strategies.

2025-01-15·Current Topics in Medicinal Chemistry

Exploring the Therapeutic Potential of Natural Flavonoids in Inflammatory Bowel Disease: Insights into Intestinal Mucosal Barrier Regulation

Article

作者: Wang, Min ; Li, Yaxin ; Wang, Shuo ; Zhang, Yanqing ; Cao, Yuxin ; Zhang, Mengyu ; Liu, Jinrui ; Xie, Junbo

Inflammatory Bowel Disease (IBD) is a chronic non-specific disease that affects the gastrointestinal tract, and Intestinal Mucosal Barrier (IMB) damage is closely related to its pathogenesis. The management of IBD often involves repairing the mechanical, chemical, immune, or biological barriers of the intestinal mucosa to alleviate symptoms. Currently, the treatment of IBD patients requires continuous medication or surgical interventions, which can cause irreversible damage to the patient's body over time. Natural flavonoids, commonly found in human diets, offer a safe, effective, and non-toxic alternative, presenting significant potential for promoting intestinal health and disease prevention. This article aimed to explore current research concerning the role of natural flavonoids in modulating the IMB in IBD, offering a new perspective for the prevention and management of IBD and highlighting new opportunities for the development and application of natural flavonoids.

2025-01-01·Internal Medicine

Development of Graves' Disease after Resection of an Autonomously Functioning Thyroid Nodule

Article

作者: Nakamura, Shigenori

We herein report a 46-year-old woman with autonomously functioning thyroid nodules (AFTNs) who developed Graves' disease (GD) approximately one year after AFTN resection. Before surgery, the patient was positive for TgAb and TPOAb, and negative for TRAb. An AFTN is a follicular adenoma surrounded by chronic thyroiditis. At the onset of GD, her TgAb and TPOAb titers increased, and TRAb became positive. This case suggests that surgery releases a large amount of thyroid tissue that contains thyroid-stimulating hormone receptors, leading to GD in susceptible individuals. Preoperative chronic thyroiditis can predict the postoperative development of GD.

项与慢性甲状腺炎相关的新闻（医药）

2023-02-10

·生物制药小编

修美乐与Dupixent，自免领域中的不同策略

自免药物在药物开发领域方面一直拥有重要的地位，随着全球人口老龄化和生活方式改变，免疫性疾病的发病率正在上升。这一增长势头也造就了修美乐的数年的强势期。自从2003年修美乐在美国首次获得批准上市，便在十年里一直占据全球药品销售额榜首的位置。在修美乐开始衰退之时，自免领域的另外一款药物Dupixent展现出了高速增长的势头。不过这两款药的作用机制非常不同：Dupixent以抑制IL-4/IL-13信号通路；而修美乐抑制TNF-α的信号通路，这两款药分别在Th1和Th2上展现了各自的策略。TNF-α与IL4/IL13在免疫系统中，Th1和Th2是指T细胞的两种分化方向，在自身免疫疾病中起到重要作用。Th1（T helper 1）是一种免疫系统中的细胞，其主要作用是对抗细菌和病毒感染。它们产生许多免疫系统激活的因子，如白介素-2（IL-2）和白介素-12（IL-12），促进其他免疫细胞的活化。Th2（T helper 2）是另一种免疫系统中的细胞，主要作用是对抗寄生虫和和螨虫的免疫应答。它们产生许多免疫系统抑制的因子，如白介素-4（IL-4）和白介素-13（IL-13），促进免疫应答的抑制。在自身免疫疾病中，通常存在Th1和Th2的不平衡，导致免疫系统对自身组织产生攻击，从而诱发疾病的发生。因此，调节Th1和Th2平衡在治疗自身免疫性疾病中非常重要。Th1与Th2的平衡很多自免疾病中存在细胞因子不平衡的情况：比如类风湿关节炎、莱姆病、多发性硬化症、胰岛素依赖型糖尿病和慢性甲状腺炎中，Th1及其细胞因子占优势，这些疾病可被归为Th1状态；但是在过敏性疾病、哮喘、硬皮病、系统性红斑狼疮以及HIV感染中，Th2及其细胞因子占优势，处于Th2状态。尤其在自身免疫疾病中，Th2细胞活跃过多，导致过度炎症。总的来说：Th1型细胞因子主要为炎症性细胞因子，而Th2型细胞因子则有抗炎效应。而针对Th1与Th2开发的自免药物便是两种不同的成药策略，它们所对应的适应症也不同。修美乐（TNF-α）与Dupixent（IL4/IL13）便分别是这两种不同策略的自免药物。TNF-αTNF-α是一种炎症介质，在Th1失衡的情况下它的水平升高。TNF-α在自免疾病中能促进细胞介导的炎症，诱导白细胞介素产生以及调节免疫系统的代谢。TNF-α与自免疾病相关的疾病包括类风湿性关节炎、肌肉红斑狼疮、溃疡性结肠炎、脊柱间盘疾病以及银屑病等等。阻断TNF-α的作用可以缓解炎症，进而缓解Th1失衡导致的疾病。因此，TNF-α是许多治疗自身免疫性疾病的药物（如修美乐）的靶点。IL-4白细胞介素-4 （IL-4）是一种免疫细胞介素，主要通过调节免疫细胞活性和功能来参与免疫应答。在自身免疫疾病中，IL-4可能在细胞因子的失衡的情况下引发或加重疾病。尤其是可以促进Th2细胞的生长和活性，进而导致Th2细胞产生过多的细胞因子，会产生如哮喘、过敏性紫癜和特应性皮炎等疾病。因此，阻断IL-4的作用可以作为自身免疫疾病的治疗策略。参与特应性皮炎的免疫细胞来源：闲谈ImmunologyIL-13白细胞介素13（IL-13）是由活化的Th2产生的细胞因子，在许多自身免疫性疾病的发展中起着至关重要的作用。IL-13参与免疫系统的调节，并引起各种免疫细胞的激活，如嗜酸性粒细胞，成纤维细胞和平滑肌细胞。在自身免疫性疾病中，IL-13的过度产生可导致抗体的产生和免疫细胞的激活，从而导致炎症和组织损伤。这可能导致哮喘、特应性皮炎和嗜酸性粒细胞性食管炎等疾病。因此，IL-13同样是治疗这些自身免疫性疾病的潜在治疗靶点。增速迅猛的Dupixent2017年3月，由赛诺菲和再生元共同研制的Dupixent在美上市。Dupixent的适应症包括特应性皮炎（AD）、哮喘、慢性鼻-鼻窦炎伴鼻息肉 (CRSWNP) 、结节性痒疹、嗜酸性食管炎临床需求的持续释放。根据近日赛诺菲的财报来看，赛诺菲的Dupixent2022年其销售收入为86亿美元，同比增长43.8%，成为全年收入增长的主要驱动力。赛诺菲预计2023年Dupixent的销售额将突破百亿大关，成为超级重磅炸弹药物。2022的Dupixent销售额增长目前，它治疗慢性自发性荨麻疹（CSU）的监管申请正在接受美国FDA的审评。用于治疗2型慢阻肺（COPD）的两项3期临床试验正在进行中。Dupixent具有治疗多种2型炎症的潜力小结随着对自免疾病的认识不断加深，越来越多的药物正在研发和上市，并取得了显著的临床效果。曾经的修美乐乃至后起的Dupixent覆盖了众多的自免领域适应症，均拿下了耀眼夺目的成绩单。随着各大药企的不断研发，乃至国内药企在IL-4和IL-13管线上的不断布局跟进，未来在免疫治疗领域药物前景将不断向前，造就多个重磅药物。参考资料：1.https://3g.163.com/dy/article/HL8VH5UG055308M5.html2.https://mp.weixin.qq.com/s/pd19RlKvEIZ0Y5w78ak_Lw3.https://www.sanofi.com

免疫疗法临床结果上市批准